Michael Ciancanelli
Director, Translational and Clinical Sciences at Turnstone Biologics - New York, NY, US
Michael Ciancanelli's Colleagues at Turnstone Biologics
Michael Ciancanelli's Contact Details
347-897-5988
New York City Metropolitan Area
Turnstone Biologics
Michael Ciancanelli's Company Details
Turnstone Biologics, a privately held clinical stage biotechnology company, is developing new medicines to treat and cure solid tumors by pioneering differentiated approaches with two clinically validated technologies. Turnstone's innovative tumor infiltrating lymphocyte (TIL) therapy, which is designed to extend the efficacy of TILs to a majority of solid tumor indications by selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) for tumor eradication, represents the Company's foundational therapeutic modality driving its cancer immunotherapy pipeline. The Company's lead TIL therapy candidate, TIDAL-01, is expected to enter clinical trials in 2022. Turnstone also is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including their use in combination with the Company's novel viral immunotherapies. Built on a proprietary vaccinia virus platform, Turnstone is evaluating its lead viral immunotherapy program, RIVAL-01/TAK-605, in an ongoing Phase 1/2a trial as part of a global collaboration with Takeda.